Å·ÃÀAV

• 12:00 Registration, exhibition and lunch
• 13:00 Opening remarks
• 13:10 Antibiotics: challenges and opportunities - Dr Stephen Baker, GlaxoSmithKline
• 13:55 Rational and irrational discovery of novel interventions to treat drug-resistant infections - Prof Matt Cooper, University of Queensland and Inflazome
• 14:40 Flash poster presentations
• 15:00 Refreshment break and exhibition
• 15.30 Towards photopharmacological antimicrobial chemotherapy - Dr Matthew Fuchter, Imperial College London
• 16:00 SPARKing new antibiotic discovery - Wes King, The Pew Charitable Trusts
• 16.30 Research and development of new antimicrobial drugs and combinations: a not-for-profit approach - Prof Laura Piddock, Global Antibiotic Research & Development Partnership
• 17:15 Networking and refreshments

• 09:00 Rules for bacterial penetration - what we know and what we don't - Dr Paul Finn, Oxford Drug Design
• 09:30 Reversing efflux-mediated resistance to reinvent broad-spectrum antibiotics  -Dr K Miraz Rahman, King’s College London
• 10:00 Predictive guidelines for compound accumulation lead to new broad-spectrum antibiotics - Prof Paul Hergenrother, University of Illinois
• 10:45 Refreshment break and exhibition
• 11:15 Non-hydroxamate LpxC inhibitors - Dr Alastair Parkes, Evotec
• 11:45 Novel immunotherapeutics to target Gram-negative bacterial infections - Dr Emma Leire, Centauri Therapeutics
• 12:15 Analysis of poatassium (K+) efflux systems (Kef) as an antibiotic target n pathogenic bacteria - Catherine Haslam, University of Oxford
• 12:30 Turning strength in to weakness: exploiting resistance as a novel therapeutic target - Lindsay Evans, Imperial College, London
• 12.45 MAPS: Multiparameter Assay for Profiling Susceptibiity - Dr Lisa Miller, University of York
• 13:00 Lunch and exhibition
• 14:00 Short antimicrobial peptides - their potential against multidrug-resistant bacteria - Dr Kai Hilpert, St George’s, University of London
• 14:30 From HTS to preclinical candidate: a novel small-molecule antibiotic for the treatment of drug-resistant Neisseria gonorrhoeae - Dr Paul Meo, Summit Therapeutics
• 15:00 Refreshment break and exhibition
• 15:30 Metallo β-lactamase inhibitors: an approach to combat the threat of emerging carbapenem resistance due to metallo β-lactamase enzymes in Gram-negative bacteria - Dr David Davies, AntaBio
• 16:00 Challenges in antibacterial drug discovery - Prof Ian Gilbert, University of Dundee
• 16:45 Closing remarks

SCI, 14/15 Belgrave Square, London , SW1X 8PS, United Kingdom